Protection for CD4+ T Cell-Mediated Antiviral ...

Qualitative and Quantitative Requirements for CD4+ T Cell-Mediated Antiviral Protection This information is current as of June 2, 2013.

Kevin J. Maloy, Christoph Burkhart, Giulia Freer, Thomas Rülicke, Hanspeter Pircher, Dwight H. Kono, Argyrios N. Theofilopoulos, Burkhard Ludewig, Urs Hoffmann-Rohrer, Rolf M. Zinkernagel and Hans Hengartner J Immunol 1999; 162:2867-2874; ; http://www.jimmunol.org/content/162/5/2867

Subscriptions Permissions Email Alerts

This article cites 66 articles, 43 of which you can access for free at: http://www.jimmunol.org/content/162/5/2867.full#ref-list-1 Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscriptions Submit copyright permission requests at: http://www.aai.org/ji/copyright.html Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/cgi/alerts/etoc

The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 9650 Rockville Pike, Bethesda, MD 20814-3994. Copyright © 1999 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606.

Downloaded from http://www.jimmunol.org/ by guest on June 2, 2013

References

Qualitative and Quantitative Requirements for CD41 T Cell-Mediated Antiviral Protection1 Kevin J. Maloy,2,3* Christoph Burkhart,2* Giulia Freer,* Thomas Ru¨licke,* Hanspeter Pircher,* Dwight H. Kono,† Argyrios N. Theofilopoulos,† Burkhard Ludewig,* Urs Hoffmann-Rohrer,* Rolf M. Zinkernagel,* and Hans Hengartner*

T

he variety of strategies that viruses use to infect and replicate in mammalian hosts is paralleled by the diversity of immune mechanisms that these hosts have evolved to protect against infection. The particular effector mechanisms required depend primarily on the nature of the virus and the route of infection (1). In general, for noncytopathic viruses such as lymphocytic choriomeningitis virus (LCMV),4 CD81 CTL are the major effectors in the eradication of primary infection, while neutralizing Abs may assist in protecting against reinfection (2, 3). In the case of cytopathic viruses, T cell-dependent cytokines together with neutralizing Abs are usually essential for viral eradication and protection against reinfection (1, 4). CD41 T cells play a crucial role in many of these antiviral responses. As well as their direct antiviral effects via the production of cytokines such as IFN-g and TNF-a (5–10), they provide the cognate signals that induce neutralizing

*Department of Pathology, Institute of Experimental Immunology, Zurich, Switzerland; and †The Scripps Research Institute, La Jolla, CA 92037 Received for publication September 11, 1998. Accepted for publication November 13, 1998. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 1 This work was supported by grants from the Swiss National Science Foundation (31-32179.91) and the Kanton Zurich. 2

These authors contributed equally to this work.

3

Address correspondence and reprint requests to Dr. Kevin J. Maloy, Department of Pathology, Institute of Experimental Immunology, Schmelzbergstrasse 12, CH-8091 Zurich, Switzerland. E-mail address: [email protected] 4 Abbreviations used in this paper: LCMV, lymphocytic choriomeningitis virus; G, glycoprotein; VSV, vesicular stomatitis virus; Vacc-IND-G, recombinant vaccinia virus expressing the vesicular stomatitis virus serotype Indiana glycoprotein; PE, R-phycoerythrin; MACS, magnetic antibody cell sorting; VSV-IND, vesicular stomatitis virus serotype Indiana; VSV-NJ, vesicular stomatitis virus serotype New Jersey; pfu, plaque-forming units; UV-VSV, ultraviolet-inactivated vesicular stomatitis virus; Vacc-LCMV-NP, recombinant vaccinia virus expressing the lymphocytic choriomeningitis virus nucleoprotein.

Copyright © 1999 by The American Association of Immunologists

IgG responses (11), and they also enhance the magnitude and longevity of antiviral CTL responses (12–16). A number of experimental models of viral infection have emphasized the important role of CD41 T cells. For example, mice deficient in CD81 CTL can clear influenza A virus, and adoptively transferred CD41 T cell clones have been shown to be able to promote recovery from lethal infection (17–19). In addition, CD81 CTL-deficient mice can also effectively control vaccinia virus infection (20, 21). Furthermore, poliovirus-specific CD41 T cell clones are capable of adoptively transferring protection against lethal infection by stimulating neutralizing Ab production (22). Thus CD41 T cell responses may play a key role in the eradication of viruses by both humoral and cell-mediated mechanisms. Currently, however, little is known about the quantitative and qualitative characteristics of these anti-viral CD41 T cell responses. Such information would have important implications for adoptive immunotherapy of viral diseases in immunocompromised hosts, where it has already been demonstrated that anti-viral CD81 CTL responses were more efficiently reconstituted when virus-specific CD41 Th cells were cotransferred (23–25) and adoptively transferred CD41 T cells also contributed to the clearance of persistent LCMV infection from carrier mice (26). It may also have implications for the maintenance of the protective T cell repertoire to viral infections, since it has recently been shown that the memory T cell pool specific for a given virus is altered by subsequent viral infections (27). To address these issues we generated transgenic mice (tg7) expressing an MHC class II (I-Ab)-restricted TCR specific for a peptide derived from the glycoprotein (G) of VSV serotype Indiana (VSV-IND) (28). VSV infection of immunocompetent mice induces a rapid neutralizing IgM response that occurs independently of T cell help, followed by production of neutralizing IgG Abs that are strictly dependent on CD41 T cell help (11). The neutralizing 0022-1767/99/$02.00


CD41 Th cells deliver the cognate and cytokine signals that promote the production of protective virus-neutralizing IgG by specific B cells and are also able to mediate direct antiviral effector functions. To quantitatively and qualitatively analyze the antiviral functions of CD41 Th cells, we generated transgenic mice (tg7) expressing an MHC class II (I-Ab)-restricted TCR specific for a peptide derived from the glycoprotein (G) of vesicular stomatitis virus (VSV). The elevated precursor frequency of naive VSVspecific Th cells in tg7 mice led to a markedly accelerated and enhanced class switching to virus-neutralizing IgG after immunization with inactivated VSV. Furthermore, in contrast to nontransgenic controls, tg7 mice rapidly cleared a recombinant vaccinia virus expressing the VSV-G (Vacc-IND-G) from peripheral organs. By adoptive transfer of naive tg7 CD41 T cells into T cell-deficient recipients, we found that 105 transferred CD41 T cells were sufficient to induce isotype switching after challenge with a suboptimal dose of inactivated VSV. In contrast, naive transgenic CD41 T cells were unable to adoptively confer protection against peripheral infection with Vacc-IND-G. However, tg7 CD41 T cells that had been primed in vitro with VSV-G peptide were able to adoptively transfer protection against Vacc-IND-G. These results demonstrate that the antiviral properties of CD41 T cells are governed by the differentiation status of the CD41 T cell and by the type of effector response required for virus elimination. The Journal of Immunology, 1999, 162: 2867–2874.

ANTIVIRAL PROTECTION MEDIATED BY CD41 T CELLS

2868

dopregnant C57BL/6 foster females. Offspring were analyzed for integration of the transgenic TCR a- and b-chain constructs by PCR using the following primers; for Va4, 59-TTTTGAATTCGCTAAGAATCATGAA CACTGTCGA-39 and 59-AGAGGGTGCTGTCCTGAGAC-39; for Vb2, 59-AGAACCTTGTACTGCACCTGC-39 and 59-CTGTGTGACAGTTT GGGTGA-39. Double transgenic founder mice (tg7) were selected that had cointegrated the transgenic TCR constructs and transmitted them in a Mendelian manner.

Cytofluorometric analysis

IgG response seems to be crucial for recovery from primary infections and for protection against reinfection (29 –32). Furthermore, previous work in this laboratory has demonstrated that H-2b mice that have been primed with VSV rapidly eliminate a recombinant vaccinia virus expressing the VSV-IND-G from ovaries or brain in a CD41 T cell-dependent manner (7, 8, 33). Thus, using the same population of VSV-G-specific Th cells, we have analyzed qualitative and quantitative characteristics of different classes of CD41 T cell-mediated antiviral responses, the induction of VSVneutralizing IgG Abs, and the cell-mediated clearance of the recombinant vaccinia virus.

CD69 Up-regulation by CD41 T cells Lymph node cells from C57BL/6 or transgenic mice were isolated, and CD81 T cells and B cells were removed using magnetic Ab cell sorting (MACS) with anti-CD8 and anti-B220 microbeads according to the manufacturer’s instructions (Miltenyi Biotech, Bergisch Gladbach, Germany). Remaining CD41 lymph node cells (.90% pure) were resuspended in RPMI/10% FCS at 2.5 3 106/ml. C57BL/6 dendritic cells were prepared as previously described (40) and were cultured at 5 3 106 cells/ml in RPMI/ 10% FCS with 100 mg/ml p8 for 2 h at 37°C and then washed in RPMI/ 10% FCS. Aliquots of 2.5 3 105 CD41 T cells were added to an equal number of C57BL/6 dendritic cells in 96-well U-bottom plates, pelleted for 2 min by centrifugation, and incubated at 37°C for 6 h. Samples were then transferred into tubes containing 2 ml of ice-cold FACS buffer, vortexed for 30 s, and put on ice for 10 min to allow dissociation of dendritic cell-T cell clusters, which was verified by light microscopy. Samples were washed in FACS buffer, stained with PE-anti-CD4 plus FITC-anti-CD69 for 30 min on ice, and analyzed as described above.

Materials and Methods

Viruses and inactivation of VSV

Mice

VSV-IND (Mudd-Summers isolate) and VSV-NJ (Pringle Isolate) were originally obtained from D. Kolakovsky, University of Geneva (Geneva, Switzerland). They were grown on BHK 21 cells infected at low multiplicity of infection, and plaqued on Vero cells (41, 42). UV light inactivation of VSV was performed under a 15-W UV lamp (type 7 UV, Phillips, Mahway, NJ) at 10 cm from the source for 4 min (43). Inactivation of VSV was verified by plaquing on Vero cells. Recombinant vaccinia virus expressing VSV-IND-G (Vacc-IND-G) were a gift from B. Moss, Laboratory of Viral Diseases, National Institutes of Health (Bethesda, MD), and were grown on BSC 40 cells at low multiplicity of infection and plaqued on the same cells (44).

b

C57BL/6 (H-2 ) and TCR transgenic (SMARTA) mice recognizing a peptide from the LCMV-G (34), were obtained from the breeding colony of the Institut fu¨r Zuchthygiene, Tierspital (Zurich, Switzerland). Mice rendered T cell deficient by targeted disruption of the TCRa gene (TCRa2/2) (35) were obtained from Dr. M. J. Owen, Imperial Cancer Research Fund (London, U.K.) and were backcrossed five times to C57BL/6 mice to ensure a H-2b background. Mice were between 8 and 16 wk of age when first used.

Generation of ab TCR transgenic mice (tg7) For cloning of the TCR a-chain, cDNA obtained from the VSV-G-specific T cell hybridoma 31.2.10.4 (28) was used as a template for PCR amplification with a downstream primer (Ca-912; 59-ATCCGGCTACTTTCA GCAGCAG-39) harboring in the Ca region and an upstream primer (59Va4-1; 59-TTTTGAATTCGCTAAGAATCATGAACACTGTCGA-39) hybridizing with the 59 end of the leader sequence, producing a 0.65-kb fragment containing the leader sequence (L), the rearranged Va4, JaTA72, and part (224 bp) of the Ca gene segment. This fragment was then cloned into the pDPL13-derived plasmid p14a2AR containing a full Ca gene (H. Pircher, unpublished observations). The resulting 1.4-kb construct (L-Va4JaTA72-Ca) was then cloned into the BamHI/SalI site of the expression vector pHSE39 (36) (Fig. 1A). The TCR b-chain gene construct was prepared as previously described (37) (Fig. 1B). For microinjection, the linearized expression vectors depicted in Fig. 1 were isolated with silicabased beads (Prep-A-Gene, Bio-Rad, Hercules, CA). The DNA was precipitated with ethanol and diluted in 10 mM Tris-HCl (pH 7.5) containing 0.1 mM EDTA to a final concentration of 100 ng/ml. Approximately 1 ng (500 molecules) of each expression vector was injected into the pronucleus of fertilized eggs derived from C57BL/6 mice (38, 39). Surviving microinjected eggs were transferred into the oviducts of pseu-

Immunizations Mice were immunized i.v. with 2 3 106 pfu of live or UV-inactivated VSV-IND or VSV-NJ. Sera were collected by bleeding from the retroorbital plexus at different time points after injection for determination of VSV-specific neutralizing Ab titers.

Serum neutralization test VSV-neutralizing IgM and IgG Ab titers were assayed as previously described (45). Briefly, sera were prediluted 40-fold in MEM containing 5% FCS, then heat-inactivated for 30 min at 56°C. Serial 2-fold dilutions were mixed with equal volumes of VSV diluted to contain 500 pfu/ml. The mixture was incubated for 90 min at 37°C in an atmosphere with 5% CO2. One hundred microliters of the serum-virus mixture was then transferred onto Vero cell monolayers in 96-well plates and incubated for 1 h at 37°C. The monolayers were overlaid with 100 ml of DMEM containing 1% methylcellulose. After incubation for 24 h at 37°C the overlay was flicked off, and the monolayer was fixed and stained with 0.5% crystal violet. The highest dilution of serum that reduced the number of plaques by 50% was


FIGURE 1. Schematic depiction of the linearized TCRa (A) and TCRb (B) transgene constructs. Important restriction sites are given. Arrows indicate DNA stretches amplified by PCR with specific primer pairs for the identification of the TCR transgenes.

Surface expression of the TCR Vb2 transgene was determined by cytofluorometric analysis. Spleen or blood cells (5 3 105) from tg7 mice were incubated for 30 min at 4°C in FACS buffer (PBS containing 2% FCS and 20 mM EDTA) containing FITC-labeled anti-Vb2 Ab (B20.6) and PEconjugated anti-CD4 (RM4-5, both from PharMingen, Hamburg, Germany). For three-color analysis of surface activation markers, spleen cells were first stained with biotinylated Abs against CD25 (7D4), CD62-L (MEL-14), or CD69 (H1.2F3; all from PharMingen) followed by washing with FACS buffer and detection with Tri-Color-conjugated streptavidin (Caltag Laboratories, Burlingame, CA). After washing in FACS buffer, samples were analyzed using a FACScan flow cytometer and CellQuest software (Becton Dickinson, Mountain View, CA). Forward and side scatter characteristics were used to distinguish the lymphocyte population. Before analysis of peripheral blood samples, RBC were lysed with FACSlyse solution (Becton Dickinson).

The Journal of Immunology

2869

taken as the titer. To determine IgG titers, undiluted serum was pretreated with an equal volume of 0.1 M 2-ME in saline (46).

Vaccinia protection assay Female transgenic tg7 or control C57BL/6 mice were primed with either VSV-IND wild-type virus i.v. or VSV-G peptide 415– 433 (50 mg in IFA i.p.) or were left unprimed. Eight to ten days later mice were challenged with 5 3 106 pfu Vacc-IND-G i.p. Both ovaries were harvested 5 days later, and the titer of Vacc-IND-G was determined on BSC 40 monolayers as described previously (7).

T cell proliferative assays Single cell suspensions of spleen cells from normal or transgenic mice were prepared in RPMI 1640 medium (Life Technologies, Paisley, U.K.) containing 10% FCS, penicillin, streptomycin, L-glutamine, and 5 3 1025 M 2-ME. Spleen cells(4 3 105/well) were cultured in 96-well roundbottomed plates (Falcon, Becton Dickinson) at 37°C in 5% CO2 in the presence of serial threefold dilutions of Ag. After 72 h, cells were pulsed with [3H]thymidine (1 mCi/well) for 16 h and harvested, and the incorporated radioactivity was measured using a beta counter (Wallac, Turku, Finland). Results are expressed as a stimulation index that was calculated as (cpmsample/cpmspontaneous), with spontaneous counts per minute obtained using cells cultured in the absence of Ag.

Naive transgenic tg7 CD41 spleen cells were obtained at a purity of 98% by MACS purification with anti-CD4 microbeads (Miltenyi Biotech). Aliquots of 106 CD41 T cells were cultured in six-well tissue culture plates (TPP, Wohlen, Switzerland) in 5 ml of RPMI 1640 medium containing 10% FCS, penicillin, streptomycin, L-glutamine, 5 3 1025 M 2-ME, and 50 U/ml recombinant murine IL-2 (PharMingen) together with 107 irradiated C57BL/6 spleen cells and antigenic peptide p8 (amino acids 415– 433; 1 mg/ml). After 4 days of culture at 37°C in 5% CO2, cells were washed, split 1:2 in fresh medium containing 50 U/ml recombinant murine IL-2, and cultured for an additional 3– 4 days. Primed cells were then harvested and washed twice in balanced salt solution before adoptive transfer.

Cytokine analysis 6

1

Aliquots of 10 naive or primed transgenic tg7 CD4 T cells were cultured in 24-well tissue culture plates (TPP) in 1 ml of RPMI 1640 medium containing 10% FCS, penicillin, streptomycin, L-glutamine, and 5 3 1025 M 2-ME together with 5 3 106 irradiated C57BL/6 spleen cells and peptide p8 (10 mg/ml). Supernatants were harvested after 24 h (for IL-2) or 72 h (for IFN-g and IL-4) of culture at 37°C in 5% CO2. IL-2 production was determined by assaying growth of the IL-2-dependent cell line CTLL-2, with quantification of viable cells using the AlamarBlue color reaction (BioSource International, Camarillo, CA) measured by fluorescence emission at 590 nm using a CytoFluor 2350 fluorometer (Millipore, Bedford, MA). IFN-g and IL-4 were measured by ELISA, using Abs and protocols provided by PharMingen. In all cases standard curves were prepared using recombinant cytokines (PharMingen) assayed in parallel. Results are expressed as the mean cytokine concentration (units per milliliter) 6 SEM of samples assayed in triplicate.

Adoptive transfer of antiviral immunity TCRa2/2 mice or C57BL/6 mice were adoptively transferred i.v. with the indicated numbers of naive or primed transgenic CD41 T cells and challenged 24 h later with 2 3 106 pfu UV-VSV i.v. or with 5 3 106 pfu Vacc-IND-G i.p. Neutralizing Ab responses and vaccinia titers in ovaries were measured as described above.

Results

Phenotype and Ag specificity of tg7 transgenic CD41 T cells To assess quantitative and qualitative aspects of antiviral CD41 T cell function, we generated transgenic mice (tg7) expressing a IAb-restricted TCR that recognized a peptide (p8; amino acids 415– 433) derived from the VSV-G (28). FACS analysis of tg7 mice demonstrated that there were no gross abnormalities in T cell subsets present in either thymus or spleen (data not shown) and that the transgenic Vb2 TCR chain was expressed on 60 –70% of mature CD41 T cells (Fig. 2A). The transgenic Vb21CD41 T cells exhibited a phenotype characteristic of normal naive T cells, i.e., CD25low CD69low CD62Lhigh (Fig. 2B). Since a mAb against the

FIGURE 2. Phenotypic analysis of transgenic tg7 CD41 T cells. A, Spleen cells from tg7 transgenic (solid line) or control C57BL/6 (dashed line) mice were stained with FITC-anti-Vb2 and PE-anti-CD4 mAbs. The graph shows the expression of the Vb2 TCR on gated CD41 T cells. B, Expression of CD25, CD69, and CD62-L on naive (dashed lines) or p8primed (solid lines) Vb21CD41 cells from tg7 mice. Numbers shown are percentages of Vb21CD41 T cells contained within the respective markers. Plots are representative of four similar experiments.

Va4 transgene product was not available, and as allelic exclusion at the TCRa locus is much weaker than that at the TCRb locus (47), it was not certain that all the Vb21CD41 cells also expressed the transgenic a-chain. To quantify the true proportion of p8-reactive T cells in tg7 mice, we performed CD69 up-regulation studies on CD41 T cells from tg7 mice. After culture for 6 h with p8-bearing dendritic cells, about 50% of tg7 CD41 T cells expressed high levels of CD69 compared with only 5% of those cultured with dendritic cells in the absence of p8 (Fig. 3A). CD41 T cells from nontransgenic C57BL/6 mice showed no increase in CD69 expression after culture with p8-bearing dendritic cells (Fig. 3B). Thus, around 45% of mature CD41 T cells in tg7 mice were VSV-G specific. The accuracy of this method was verified using another CD41 T cell transgenic line, SMARTA, recognizing a peptide derived from the LCMV-G. Approximately 90% of SMARTA CD41 T cells up-regulated CD69 when cultured with dendritic cells bearing the LCMV-G peptide (Fig. 3C), which is equivalent to the proportion of cells bearing the transgenic Va2Vb8.3 TCR (34). The Ag specificity of the transgenic CD41 T cells was confirmed using in vitro proliferative assays. In contrast to nontransgenic C57BL/6 cells, splenocytes from tg7 mice exhibited strong proliferative responses when stimulated with UV-VSV, purified VSV-G, or peptide p8 (Fig. 4). The tg7 T cells did not mount in


In vitro priming of transgenic CD41 T cells


FIGURE 3. CD69 up-regulation by transgenic tg7 CD41 T cells. Purified CD41 T cells from tg7 transgenic (A), control C57BL/6 (B), or SMARTA transgenic (C) mice were stimulated for 6 h with dendritic cells in the absence (dashed lines) or the presence (solid lines) of 100 mg/ml VSV-G p8 (A and B) or LCMV-G p13 (C) and then stained with PE-antiCD4 plus FITC-anti-CD69 mAbs. Plots show the expression of CD69 on gated CD41 T cells and are representative of three separate experiments.

FIGURE 5. The tg7 mice exhibit enhanced VSV-IND-G-specific Th cell reactivity in vivo. Groups of naive tg7 transgenic (squares) or C57BL/6 control (circles) mice were immunized i.v. with 2 3 106 pfu of live (open symbols) or UV-inactivated VSV-IND (filled symbols; A) or with live or UV-inactivated VSV-NJ (B). On the indicated days, blood was taken, and serum was analyzed for the presence of VSV-IND neutralizing IgM and IgG. Mean titers from groups of two or three mice are shown, and intragroup variations were two titer steps or less. One of two similar experiments is shown.

vitro proliferative responses when cultured with another VSV-G Th epitope (p41) which is also presented in H-2b mice (Fig. 4) (28). These findings confirmed that tg7 mice contained a high frequency of specific T cells that recognized the VSV-G-derived p8 peptide. Tg7 mice exhibit enhanced neutralizing IgG responses after immunization with inactivated VSV-IND We next analyzed whether the increased precursor frequency of VSV-G-specific CD41 T cells present in tg7 mice correlated with an enhanced responsiveness to VSV. After immunization with live VSV, both C57BL/6 mice and tg7 mice mounted rapid, T-inde-

pendent, VSV-neutralizing IgM responses followed by class switching to neutralizing IgG Abs, which are known to be CD41 T cell dependent (Fig. 5A) (11). However, when immunized with UV-inactivated VSV, which efficiently triggers B cells while poorly priming CD41 Th cells (43), the C57BL/6 mice produced very low levels of neutralizing IgG, whereas the tg7 mice again rapidly produced high titers of neutralizing IgG Abs (Fig. 5A). This enhanced sensitivity to suboptimal immunization with inactivated VSV-IND was dependent on the p8-specific T cells in tg7 mice, since there was no augmentation in the neutralizing IgG response to immunization with inactivated VSV-NJ, which does not contain the p8 epitope (Fig. 5B) (48). Adoptively transferred tg7 CD41 T cells mediate isotype switching in vivo We next attempted to quantify the number of VSV-G-specific CD41 T cells required to mediate isotype switching in vivo. Thus, naive tg7 CD41 T cells were purified using MACS and adoptively transferred into syngeneic T cell-deficient recipients (TCRa2/2 mice), which were then challenged with UV-VSV-IND. As shown in Fig. 6, TCRa2/2 mice adoptively transferred with C57BL/6 CD41 T cells made high levels of neutralizing IgM, but failed to produce neutralizing IgG Abs after immunization with UV-VSVIND. In contrast, adoptive transfer of as few as 105 tg7 CD41 T cells enabled the TCRa2/2 mice to produce VSV-neutralizing IgG responses (Fig. 6), demonstrating that the virus-specific CD41 T cells could efficiently transfer help for antiviral humoral immunity.

FIGURE 4. Ag-specific proliferative responses of transgenic tg7 splenocytes. Spleen cells from tg7 transgenic were cultured for 72 h in the presence of UV-VSV (E), VSV-G (M), p8 (VSV-G415– 433; ‚), or p41 (VSV-G52–71; F), and proliferation was monitored by overnight incorporation of [3H]thymidine. Results shown are means from duplicate cultures and are representative of two similar experiments.

In vitro primed, but not naive, tg7 CD41 T cells can adoptively transfer cell-mediated immunity against recombinant Vacc-IND-G We next examined whether tg7 CD41 T cells could mediate cellmediated immunity against a recombinant vaccinia virus expressing the VSV-IND glycoprotein (Vacc-IND-G). Previous work in


2870


2871

this laboratory has shown that C57BL/6 mice primed with VSVIND were resistant against challenge with Vacc-IND-G and that this protection was mediated by CD41 T cells (33). In agreement with those results, we found that naive tg7 mice were as resistant to Vacc-IND-G challenge as VSV-immune or p8-primed C57BL/6 mice (Fig. 7A), showing that the p8-specific tg7 CD41 T cells could indeed mediate cell-mediated immune protection. This protection was Ag specific, since the tg7 mice were not protected against challenge with a recombinant vaccinia virus expressing an irrelevant Ag Vacc-LCMV nucleoprotein (Fig. 7A). To quantify the number of VSV-G-specific CD41 T cells required for this cell-mediated protection, we adoptively transferred naive tg7 CD41 T cells into C57BL/6 recipients and challenged them with Vacc-IND-G. However, adoptive transfer of as many as 107 naive tg7 CD41 T cells failed to offer any significant protection against Vacc-IND-G (Fig. 7B). As there is evidence that the trafficking of lymphocytes through peripheral solid organs may depend on the differentiation status of the cell (49, 50), we primed tg7 CD41 T cells with p8 peptide in vitro before adoptive transfer. The primed tg7 CD41 T cells exhibited the phenotypic characteristics of effector/memory T cells, i.e., CD25high, CD69high, CD62Llow (Fig. 2B). Adoptive transfer of $ 106 primed tg7 CD41 T cells mediated protection against Vacc-IND-G (Fig. 7C). To examine whether the ability to confer protection against vaccinia correlated with different patterns of cytokine secretion, we measured the cytokines produced by naive and primed tg7 CD41 T cells following stimulation with p8. Naive tg7 CD41 T cells produced high levels of IL-2 and only low amounts of IFN-g, while primed tg7 CD41 T cells produced similar levels of IL-2 but around 80- to 100-fold higher levels of IFN-g (Fig. 7, D and E). Neither naive nor primed tg7 CD41 T cells produced detectable amounts of IL-4 (data not shown).

Discussion

FIGURE 7. Primed, but not naive, tg7 CD41 T cells can adoptively transfer protection against peripheral vaccinia virus infection. A, Naive female C57BL/6 (open circles) or tg7 (filled circles) mice were left untreated or were primed with 2 3 106 pfu of VSV-IND i.v. or with 50 mg of p8 in IFA i.p. Eight to ten days later mice were challenged with 5 3 106 pfu of Vacc-IND-G or Vacc-LCMV nucleoprotein (Vacc-LCMV-NP) i.p. B, C57BL/6 female mice were left untreated or were primed with 2 3 106 pfu of VSV-IND i.v. or were adoptively transferred with 107 purified naive tg7 CD41 T cells i.v. One day later recipients were challenged with 5 3 106 pfu of Vacc-IND-G i.p. C, Graded numbers of in vitro primed tg7 CD41 T cells were adoptively transferred i.v. into C57BL/6 female mice. One day later recipients were challenged with 5 3 106 pfu Vacc-IND-G i.p. In all cases, 5 days after challenge ovaries were removed, and vaccinia titers were determined. Symbols represent individual mice, and bars represent mean titers. One representative experiment of three is shown. D and E, Cytokine secretion by naive and primed tg7 CD41 T cells. Supernatants collected after in vitro culture of 106 CD41 T cells with 5 3 106 syngeneic irradiated spleen cell APC in the absence (filled bars) or the presence (hatched bars) of p8 (10 mg/ml) were assayed for IL-2 (D) and IFN-g (E). Results are expressed as the mean 6 SEM of samples assayed in triplicate and are representative of two similar experiments.

In this study we generated TCR transgenic mice (tg7) that allowed us to examine the roles of CD41 T cells of identical specificity in humoral or cell-mediated antiviral protection. Our results confirmed that CD41 T cells can efficiently mediate protection against viruses that are controlled by T help-dependent neutralizing IgG Abs (VSV) or cytokines (Vacc-IND-G). However, the number and

activation state of CD41 T cells required for protection depended on the virus and the protection assay used. The tg7 mice exhibited enhanced responsiveness both in vitro and in vivo to VSV-IND, but not to VSV-NJ, which does not share


FIGURE 6. Adoptively transferred naive tg7 CD41 T cells mediate Ig class switching in vivo. Graded numbers of purified C57BL/6 or tg7 CD41 T cells were adoptively transferred i.v. into syngeneic TCRa2/2 mice. One day later recipients were immunized with 2 3 106 pfu UV-VSV-IND i.v. On the indicated days, blood was taken, and serum was analyzed for the presence of VSV-IND neutralizing IgM and IgG. Mean titers from groups of two or three mice are shown, and intragroup variations were two titer steps or less. One of two similar experiments is shown.


the p8 peptide sequence of the IND-G (48). The augmentation of the IgG responses against suboptimal Ag challenge with UV-VSV confirmed that many of the characteristics of T cell memory can be mimicked by enhanced precursor frequency in transgenic mice (37). Although cytofluorometric analysis revealed that in tg7 mice 60 –70% of the peripheral CD41 T cells expressed the transgenic TCR b-chain, analysis of CD69 up-regulation following TCR ligation showed that the actual frequency of p8-specific CD41 T cells was around 45%. Hence, adoptive transfer of humoral immunity required 105 tg7 CD41 T cells, representing about 4.5 3 104 Ag-specific CD41 T cells. Again, the number of these cells actually involved in mediating class switching is probably considerably less, as factors such as homing after transfer will also affect the availability of CD41 T cells to help B cells (51). Thus, our results suggest that relatively few Ag-specific naive CD41 T cells are capable of promoting antiviral IgG responses. In contrast to the neutralizing IgG responses, naive tg7 CD41 T cells were unable to adoptively transfer protection against recombinant vaccinia virus infection of peripheral solid organs (ovaries). However, tg7 CD41 T cells that had been preactivated with p8 in vitro were able to rapidly eradicate Vacc-IND-G from peripheral organs after adoptive transfer. This qualitative difference in the protective capacities of naive and primed CD41 T cells may be explained by at least two major mechanisms. First, the migratory patterns of naive and primed lymphocytes differ such that naive T cells recirculate through secondary lymphoid organs, while primed T cells may traffic through peripheral tissues (49, 50, 52). Second, the cytokine production characteristics of the cells may also be qualitatively and quantitatively different (53–55). In support of the latter possibility, we observed that primed CD41 T cells produced 80- to 100-fold higher levels of IFN-g than naive CD41 T cells. This difference is probably a major factor in the ability of primed CD41 T cells to protect against vaccinia, since previous studies have shown that IFN-g plays an essential role in protection against vaccinia mediated by CD41 T cells (4, 7, 9). Adoptive transfer of about 20-fold more CD41 T cells was required for eradication of peripheral vaccinia virus than for the induction of isotype switching. Two main factors could explain this quantitative difference; Ag form and localization. Class switching was assayed following i.v. injection of nonreplicating virus (UV-VSV), which is efficiently filtered out in the spleen and presented to naive T cells (56). Cell-mediated protection was assayed in the ovaries after i.p. challenge with live vaccinia, in which case requirements for antiviral protection are probably much more stringent. During the time that it takes virus Ag to reach lymphoid tissue, naive T cells to be primed, and protective T cells to emigrate to the peripheral organ and mediate effector function, the virus may continuously replicate. Interestingly, this qualitative difference in the protective capacities of naive and primed T cells has also been observed for virus-specific CD81 T cells. Thus, recently primed CD81 T cells are also able to mediate protection against peripheral vaccinia infection, but peripheral protection is relatively short-lived in the absence of further antigenic restimulation, which enhances extravasation of CD81 memory T cells (57–59). Thus, it appears that both CD41 and CD81 T cell-mediated antiviral protection in peripheral tissues is dependent on the presence of recently Ag-activated effector T cells rather than merely an elevated frequency of Ag-specific T cells. One paradoxical finding of this study was that naive tg7 mice were resistant against challenge with Vacc-IND-G, while naive tg7 CD41 T cells isolated from these mice were unable to adoptively transfer protection against Vacc-IND-G. Two factors may contribute to this discrepancy. First, since the adoptively transferred transgenic CD41 T cells must compete with endogenous lymphocytes

for space in lymphoid tissues, the B6 recipient mice will still have many fewer VSV-G-specific CD41 T cells than the tg7 transgenic mice. A second factor may be the expression of endogenous TCRa-chains by tg7 CD41 T cells, which could pair with the transgenic TCR Vb2 chain, giving rise to T cells bearing two different TCRs (47, 60, 61). Normal mice and humans also contain a small population of dual TCR-bearing T cells, which may be triggered via either TCR (62– 64). This situation has been reported in other TCR transgenic mice, where the existence of transgenic T cells exhibiting a memory phenotype was observed in the absence of specific Ag priming (61). Priming may have occurred through environmental Ag stimulation of the second TCR, since T cells with a memory phenotype were not observed when the tg TCR mice were crossed onto a recombination-activating gene2/2 background (61). In the tg7 mice most environmentally primed CD41 T cells capable of trafficking through tissues will also possess the transgenic TCR and thus be able to mediate peripheral protection against the recombinant vaccinia virus. Most class II MHC-restricted TCR transgenic mouse strains described to date express TCRs specific for model protein Ags, and while these have proved very useful for studying the development and differentiation of CD41 T cells, they do not permit analysis of protective immune responses mediated by CD41 T cells in vivo. Recently, a few class II-restricted TCR transgenic mouse strains specific for Ags derived from pathogens have been described (34, 65– 67). Mice expressing a transgenic TCR recognizing a class II MHC-restricted epitope of the influenza hemagglutinin exhibited only slightly higher resistance to lethal influenza infection than nontransgenic littermates (65). Interestingly, these mice did not make higher titers of hemagglutinin-specific Abs, and the protective effect seemed to be due to enhanced class I MHC-restricted and class II MHC-restricted cytotoxicity (65). Similarly, a recombinant influenza virus expressing a class II MHC-restricted peptide from hen egg lysozyme was cleared with similar kinetics by normal and HEL-specific TCRab transgenic mice (66). Furthermore, previous studies in our laboratory have shown that mice transgenic for a class II MHC-restricted TCR recognizing an epitope in the LCMV-G fail to efficiently control LCMV infection (34), confirming that clearance of LCMV is crucially dependent on CD81 CTL (2, 21). Conversely, it has been shown that mice expressing a single transgenic TCR-ab recognizing a Leishmania Ag class II MHC-restricted epitope could significantly control Leishmania major infection, and in this case protection correlated with the development of a Th1 response in both CD41 and CD4282 transgenic T cells (67). These studies, together with the results described in this paper, show that CD41 T cells may mediate a wide range of immune responses to pathogens and that their protective capabilities may differ depending on the type of response required for pathogen elimination. This transgenic model should permit further analyses of antiviral properties of CD41 T cells during different viral infections, particularly in terms of phenotype and effector function of the various subpopulations of CD41 T cells.

References 1. Zinkernagel, R. M. 1996. Immunology taught by viruses. Science 271:173. 2. Ka¨gi, D., B. Ledermann, K. Bu¨rki, P. Seiler, B. Odermatt, K. J. Olsen, E. Podack, R. M. Zinkernagel, and H. Hengartner. 1994. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369:31. 3. Seiler, P., M.-A. Bru¨ndler, C. Zimmermann, D. Weibel, M. Bruns, H. Hengartner, and R. M. Zinkernagel. 1998. Induction of protective cytotoxic T cell responses in the presence of high titers of virus-neutralizing antibodies: implications for passive and active immunization. J. Exp. Med. 187:649. 4. Ramshaw, I. A., A. J. Ramsay, G. Karupiah, M. S. Rolph, S. Mahalingam, and J. C. Ruby. 1997. Cytokines and immunity to viral infections. Immunol. Rev. 159:119.


2872


30. Gobet, R., A. Cerny, E. Ru¨edi, H. Hengartner, and R. M. Zinkernagel. 1988. The role of antibodies in natural and acquired resistance of mice to vesicular stomatitis virus. Exp. Cell Biol. 56:175. 31. Bachmann, M. F., A. Althage, T. M. Ku¨ndig, C. P. Kalberer, H. Hengartner, and R. M. Zinkernagel. 1994. How many specific B cells are needed to protect against a virus? J. Immunol. 152:4235. 32. Thomsen, A. R., A. Nansen, C. Anderson, J. Johansen, O. Marker, and J. P. Christensen. 1997. Cooperation of B and T cells is required for survival of mice infected with vesicular stomatits virus. Int. Immunol. 9:1757. 33. Ku¨ndig, T., I. Castelmur, M. F. Bachmann, D. Abraham, D. Binder, H. Hengartner, and R. M. Zinkernagel. 1993. Fewer protective cytotoxic T cell epitopes than T helper cell epitopes on vesicular stomatitis virus. J. Virol. 67:3680. 34. Oxenius, A., M. F. Bachmann, R. M. Zinkernagel, and H. Hengartner. 1998. Virus-specific MHC class II-restricted TCR-transgenic mice: effects on humoral and cellular immune responses after viral infection. Eur. J. Immunol. 28:390. 35. Philpott, K. L., J. L. Viney, G. Kay, S. Rastan, E. M. Gardiner, S. Chae, A. C. Hayday, and M. J. Owen. 1992. Lymphoid development in mice congenitally lacking T cell receptor ab-expressing cells. Science 256:1448. 36. Pircher, H. P., K. Bu¨rki, R. Lang, H. Hengartner, and R. M. Zinkernagel. 1989. Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature 342:559. 37. Freer, G., C. Burkhart, T. Ru¨licke, E. Ghelardi, U. Hoffmann Rohrer, H. Pircher, R. M. Zinkernagel, and H. Hengartner. 1995. Role of T helper cell precursor frequency on vesicular stomatitis virus neutralizing antibody responses in a T cell receptor b chain transgenic mouse. Eur. J. Immunol. 25:1410. 38. Brinster, R. L., H. Y. Chen, M. Trumbauer, A. W. Senear, R. Warren, and R. D. Palmiter. 1981. Somatic expression of herpes thymidine kinase in mice following injection of a fusion gene into eggs. Cell 27:223. 39. Hogan, B., F. Constantini, and E. Lacy. 1986. Manipulating the Mouse Embryo: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. 40. Ludewig, B., S. Ehl, U. Karrer, B. Odermatt, H. Hengartner, and R. M. Zinkernagel. 1998. Dendritic cells efficiently induce protective antiviral immunity. J. Virol. 72:3812. 41. McCaren, L., J. J. Holland, and J. T. Syverton. 1959. The mammalian cell-virus relationship. I. Attachment of poliovirus to cultivated cells of primate and nonprimate origin. J. Exp. Med. 109:475. 42. Charan, S., and R. M. Zinkernagel. 1986. Antibody mediated suppression of secondary IgM response in nude mice against vesicular stomatitis virus. J. Immunol. 136:3057. 43. Bachmann, M. F., T. M. Ku¨ndig, C. Kalberer, H. Hengartner, and R. M. Zinkernagel. 1993. Formalin inactivation of vesicular stomatitis virus impairs T cell- but not T helper independent B cell responses. J. Virol. 67:3917. 44. Mackett, M., T. Yilma, J. K. Rose, and B. Moss. 1985. Vaccinia virus recombinants: expression of VSV genes and protective immunization of mice and cattle. Science 227:433. 45. Wagner, R. R., R. M. Snyder, and S. Yamazaki. 1970. Proteins of vesicular stomatitis virus: kinetics and cellular sites of synthesis. J. Virol. 5:548. 46. Scott, D. W., and R. K. Gershon. 1970. Determination of total and mercaptoethanol-resistant antibody in the same serum sample. Clin. Exp. Immunol. 6:313. 47. Malissen, M., J. Trucy, E. Jouvin-Marche, P. A. Cazenave, R. Scollay, and B. Malissen. 1992. Regulation of TCR a and b gene allelic exclusion during T-cell development. Immunol. Today 13:315. 48. Gallione, C. J., and J. K. Rose. 1983. Nucleotide sequence of a cDNA clone encoding the entire glycoprotein from the New Jersey serotype of vesicular stomatitis virus. J. Virol. 46:162. 49. Mackay, C. R., W. L. Marston, and L. Dudler. 1990. Naive and memory T cells show distinct pathways of lymphocyte recirculation. J. Exp. Med. 171:801. 50. Mackay, C. R. 1993. Homing of naive, memory and effector lymphocytes. Curr. Opin. Immunol. 5:423. 51. Butcher, E. C., and L. J. Picker. 1996. Lymphocyte homing and homeostasis. Science 272:60. 52. Lee, W. T., and E. S. Vitetta. 1991. The differential expression of homing and adhesion molecules on virgin and memory T cells in the mouse. Cell. Immunol. 132:215. 53. Swain, S. L., L. M. Bradley, M. Croft, S. Tonkonogy, G. Atkins, A. D. Weinberg, D. D. Duncan, S. M. Hedrick, R. W. Dutton, and G. Huston. 1991. Helper T cell subsets: phenotype, function and the role of lymphokines in regulating their development. Immunol. Rev. 123:115. 54. Seder, R. A., and W. E. Paul. 1994. Acquisition of lymphokine-producing phenotype by CD41 T cells. Annu. Rev. Immunol. 12:635. 55. Constant, S., M. Zain, J. West, T. Pasqualini, P. Ranney, and K. Bottomly. 1994. Are primed CD41 T lymphocytes different from unprimed cells? Eur. J. Immunol. 24:1073. 56. Bachmann, M. F., T. M. Ku¨ndig, B. Odermatt, H. Hengartner, and R. M. Zinkernagel. 1994. Free recirculation of memory B cells versus antigen-dependent differentiation to antibody forming cells. J. Immunol. 153:3386.


5. Czarniecki, C. W., C. W. Fennie, D. B. Powers, and D. A. Estell. 1984. Synergistic antiviral and antiproliferative activities of Escherichia coli-derived human a, b, and g interferons. J. Virol. 49:490. 6. Wong, G. H. W., and D. Goeddel. 1986. Tumour necrosis factors a and b inhibit virus replication and synergize with interferons. Nature 323:819. 7. Binder, D., and T. M. Ku¨ndig. 1991. Antiviral protection by CD81 versus CD41 T cells: CD81 T cells correlating with cytotoxic activity in vitro are more efficient in antivaccinia virus protection than CD4-dependent interleukins. J. Immunol. 146:4301. 8. Ku¨ndig, T. M., H. Hengartner, and R. M. Zinkernagel. 1993. T cell dependent interferon g exerts an antiviral effect in the central nervous system but not in peripheral solid organs. J. Immunol. 150:2316. 9. Ramshaw, I., J. Ruby, A. Ramsay, G. Ada, and G. Karupiah. 1992. Expression of cytokines by recombinant vaccinia viruses: a model for studying cytokines in virus infections in vivo. Immunol. Rev. 127:157. 10. Ramsay, A. J., J. Ruby, and I. A. Ramshaw. 1993. A case for cytokines as effector molecules in the resolution of virus infection. Immunol. Today 14:155. 11. Leist, T. P., S. P. Cobbold, H. Waldmann, M. Aguet, and R. M. Zinkernagel. 1987. Functional analysis of T lymphocyte subsets in antiviral host defense. J. Immunol. 138:2278. 12. Kasaian, M. T., M. K. Leite, and C. A. Biron. 1991. The role of CD41 cells in sustaining lymphocyte proliferation during lymphocytic choriomeningitis virus infection. J. Immunol. 146:1955. 13. Leist, T. P., M. Kohler, and R. M. Zinkernagel. 1989. Impaired generation of antiviral cytotoxicity against lymphocytic choriomeningitis and vaccinia virus in mice treated with CD4-specific monoclonal antibody. Scand. J. Immunol. 30:679. 14. Matloubian, M., R. J. Conception, and R. Ahmed. 1994. CD41 T cells are required to sustain CD81 cytotoxic T cell responses during chronic viral infection. J. Virol. 68:8056. 15. Cousens, L. P., J. S. Orange, and C. A. Biron. 1995. Endogenous IL-2 contributes to T cell expansion and IFN-g production during lymphocytic choriomeningitis virus infection. J. Immunol. 155:5690. 16. von Herrath, M. G., M. Yokoyama, J. Dockter, M. B. A. Oldstone, and J. L. Whitton. 1996. CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J. Virol. 70:1072. 17. Eichelberger, M., W. Allan, M. Zijlstra, R. Jaenisch, and P. C. Doherty. 1991. Clearance of influenza virus respiratory infection in mice lacking class I major histocompatibility complex-restricted CD81 T cells. J. Exp. Med. 174:875. 18. Scherle, P. A., G. Palladino, and W. Gerhard. 1992. Mice can recover from pulmonary influenza virus infection in the absence of class I-restricted cytotoxic T cells. J. Immunol. 148:212. 19. Graham, M. B., V. L. Braciale, and T. J. Braciale. 1994. Influenza virus-specific CD41 T helper type 2 T lymphocytes do not promote recovery from experimental virus infection. J. Exp. Med. 180:1273. 20. Spriggs, M. K., B. H. Koller, T. Sato, P. J. Morrissey, W. C. Fanslow, O. Smithies, R. F. Voice, M. B. Widmer, and C. R. Maliszewski. 1992. b2Microglobulin2, CD81 T-cell-deficient mice survive inoculation with high doses of vaccinia virus and exhibit altered IgG responses. Proc. Natl. Acad. Sci. USA 89:6070. 21. Ka¨gi, D., P. Seiler, J. Pavlovic, B. Ledermann, K. Bu¨rki, R. M. Zinkernagel, and H. Hengartner. 1995. The roles of perforin and Fas-dependent cytotoxicity in protection against cytopathic and non-cytopathic viruses. Eur. J. Immunol. 25: 3256. 22. Mahon, B. P., K. Katrak, A. Nomoto, A. Macadam, P. D. Minor, and K. H. G. Mills. 1995. Poliovirus-specific CD41 T cell clones with both cytotoxic and helper activity mediate protective humoral immunity against a lethal poliovirus infection in transgenic mice expressing the human poliovirus receptor. J. Exp. Med. 181:1285. 23. Reddehase, M. J., W. Mutter, and U. H. Koszinowski. 1987. In vivo application of recombinant interleukin 2 in the immunotherapy of established cytomegalovirus infection. J. Exp. Med. 165:650. 24. Papadopoulos, E. B., M. Ladanyi, D. Emanuel, S. Mackinnon, F. Boulad, M. H. Carabasi, H. Castro-Malaspina, B. H. Childs, A. P. Gillio, T. N. Small, et al. 1994. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med. 330:1185. 25. Riddell, S. R., and P. D. Greenberg. 1995. Principles for adoptive T cell therapy of human viral diseases. Annu. Rev. Immunol. 13:545. 26. Planz, O., S. Ehl, E. Furrer, E. Horvath, M.-A. Bru¨ndler, H. Hengartner, and R. M. Zinkernagel. 1997. A critical role for neutralizing-antibody-producing B cells, CD41 T cells, and interferons in persistent and acute infections of mice with lymphocytic choriomeningitis virus: implications for adoptive immunotherapy of virus carriers. Proc. Natl. Acad. Sci. USA 94:6874. 27. Selin, L. K., K. Vergilis, R. M. Welsh, and S. R. Nahill. 1996. Reduction of otherwise remarkably stable virus-specific cytotoxic T lymphocyte memory by heterologous viral infections. J. Exp. Med. 183:2489. 28. Burkhart, C., G. Freer, R. Castro, L. Adorini, K. H. Wiesmu¨ller, R. M. Zinkernagel, and H. Hengartner. 1994. Characterization of T helper epitopes of the glycoprotein of vesicular stomatitis virus. J. Virol. 68:1573. 29. Lefrancois, L. 1984. Protection against lethal viral infection by neutralizing and nonneutralizing monoclonal antibodies: distinct mechanisms of action in vivo. J. Virol. 51:208.

2873

2874


57. Ku¨ndig, T. M., M. F. Bachmann, P. S. Ohashi, H. Pircher, H. Hengartner, and R. M. Zinkernagel. 1996. On T cell memory: arguments for antigen-dependence. Immunol. Rev. 150:63. 58. Bachmann, M. F., T. M. Ku¨ndig, H. Hengartner, and R. M. Zinkernagel. 1997. Protection against immunopathological consequences of a viral infection by activated but not resting cytotoxic T cells: T cell memory without “memory T cells?” Proc. Natl. Acad. Sci. USA 94:640. 59. Ku¨ndig, T. M., M. F. Bachmann, S. Oehen, U. W. Hoffmann, J. J. L. Simard, C. P. Kalberer, H. Pircher, P. S. Ohashi, H. Hengartner, and R. M. Zinkernagel. 1996. On the role of antigen in maintaining cytotoxic T-cell memory. Proc. Natl. Acad. Sci. USA 93:9716. 60. Heath, W. R., and J. F. A. P. Miller. 1993. Expression of two a chains on the surface of T cells in T cell receptor transgenic mice. J. Exp. Med. 178:1807. 61. Lee, W. T., J. Cole-Calkins, and N. E. Street. 1996. Memory T cell development in the absence of specific antigen priming. J. Immunol. 157:5300. 62. Padovan, E., G. Casorati, P. Dellabona, S. Meyer, M. Brockhaus, and A. Lanzavecchia. 1993. Expression of two T cell receptor a chains: dual receptor T cells. Science 262:422.

63. Padovan, E., C. Giachino, M. Cella, S. Valitutti, O. Acuto, and A. Lanzavecchia. 1995. Normal T lymphocytes can express two different T cell receptor b chains: implications for the mechanism of allelic exclusion. J. Exp. Med. 181:1587. 64. Heath, W. R., F. R. Carbone, P. Bertolino, J. Kelly, S. Cose, and J. F. A. P. Miller. 1995. Expression of two T cell receptor a chains on the surface of normal murine T cells. Eur. J. Immunol. 25:1617. 65. Bot, A., S. Casares, S. Bot, H. von Boehmer, and C. Bona. 1998. Cellular mechanisms involved in protection against influenza virus infection in transgenic mice expressing a TCR receptor specific for class II hemagglutinin peptide in CD41 and CD81 T cells. J. Immunol. 160:4500. 66. Walker, W. S., M. R. Castrucci, M. Y. Sangster, R. T. Carson, and Y. Kawaoka. 1997. HEL-Flu: an influenza virus containing the hen egg lysozyme epitope recognized by CD41 T cells from mice transgenic for an ab TCR. J. Immunol. 159:2563. 67. Reiner, S. L., D. J. Fowell, N. H. Moskowitz, K. Swier, D. R. Brown, C. R. Brown, C. W. Turck, P. A. Scott, N. Killeen, and R. M. Locksley. 1998. Control of Leishmania major by a monoclonal ab T cell repertoire. J. Immunol. 160:884.
